RenovoRx, Inc. (RNXT)
- Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
LOS ALTOS, Calif., April 18, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq L
- Business Wire
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
LOS ALTOS, Calif., April 16, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah. Clinical data was presented by David Sperling, MD, Associate Professor of Radi
- Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
LOS ALTOS, Calif., April 15, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.
